Assessment of the degree of an epigenetic field defect is a promising cancer risk marker that takes account of life history.
No takes yet. Share an insight, caveat, or question.
Asada et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: